Regeneron Pharmaceuticals (REGN) Stock Highlights

701.85 | -0.9%

2024-12-21 00:13:01

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Statistics

Range Today

700.83 717.61

Volume Today 1.87M

Range 1 Year

693 1211.2

Volume 1 Year 142.27M

Range 3 Year

538.01 1211.2

Volume 3 Year 460.69M

Range 10 Year

271.37 1211.2

Volume 10 Year 2.01B

Highlights

Market Capitalization 77.13B (large)

Floating Shares 103.1M

Current Price 701.85

Price To Earnings 17.56

Price To Revenue 4.99

Price To Book 2.58

Earnings Per Share 40.44

Payout Ratio 0%

Performance

Latest -0.9%

1 Month -5.44%

3 Months -38.76%

6 Months -32.41%

1 Year -17.43%

3 Years +13.07%

5 Years +87.19%

10 Years +66.71%

Benchmarks

Market Capitalization

2 / 368

Gross Profits

3 / 278

Total Revenue

1 / 300

Total Rank

246 / 368

Free Cashflow

2 / 352

Performance 5 years

62 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.